Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Biography

Meet the Editorial Board Member

Author(s): Henry S. Friedman

Volume 17, Issue 3, 2021

Page: [171 - 172] Pages: 2

DOI: 10.2174/157339471703210824150229

Next »
[1]
Friedman HS, Burger PC, Bigner SH, Trojanowski J, Halperin EC, Bigner DD. Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283. Med J Neuropathol Exp Neurol 1985; 44: 592-605.
[2]
Friedman HS, Burger PC, Bigner SH, et al. Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc. Am J Pathol 1988; 130: 472-84.
[3]
Friedman HS, Colvin OM, Skapek SX, et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 1988; 48: 4189-95.
[4]
Friedman HS, Schold SC, Mahaley MS, et al. Phase II treatment of medulloblastoma and pineoblastoma with melphalan: Clinical therapy based on experimental models of human medulloblastoma. J Clin Oncol 1989; 7: 904-11.
[5]
Friedman HS, Colvin OM, Kaufman SH, et al. Cyclophosphamide resistance in medulloblastoma. Cancer Res 1992; 52: 5373-8.
[6]
Dong Q, Barsky D, Colvin ME, et al. A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5′-d (GAC). Proc Natl Acad Sci USA 1995; 92: 12170-4.
[7]
Friedman HS, Krischer JP, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: A Pediatric Oncology Group randomized phase II study. J Clin Oncol 1992; 10: 249-56.
[8]
Friedman HS, Johnson SP, Dong Q, et al. Marcelli, S., Bigner, D.D., and Modrich, P.: Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 1997; 57: 2933-6.
[9]
Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkytransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998; 16: 3851-7.
[10]
Bacolod MD, Johnson SP, Pegg AE, et al. Brain tumor cell lines resistant to O6-benzylguanine/BCNU chemotherapy have O6-alkylguanine-DNA alkyltransferase (AGT) mutations. Mol Cancer Ther 2005; 3: 1127-35.
[11]
Maxwell JA, Johnson SP, McLendon RE, et al. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res 2008; 14: 4859-68.
[12]
Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13(4): 1253-9.
[13]
Friedman H, Prados M, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27(28): 4733-40.
[14]
Prados M, Cloughesy T, Samant M, et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncol 2011; 13(1): 143-51.
[15]
Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE II, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, and Friedman HS. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 2011; 17(12): 4119-24.

Rights & Permissions Print Cite
Article Metrics
15
© 2024 Bentham Science Publishers | Privacy Policy